These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
404 related articles for article (PubMed ID: 33336070)
1. A review of current progress in triple-negative breast cancer therapy. Shen M; Pan H; Chen Y; Xu YH; Yang W; Wu Z Open Med (Wars); 2020; 15(1):1143-1149. PubMed ID: 33336070 [TBL] [Abstract][Full Text] [Related]
3. Triple-negative breast cancer: recent treatment advances. Bergin ART; Loi S F1000Res; 2019; 8():. PubMed ID: 31448088 [TBL] [Abstract][Full Text] [Related]
4. Nab-paclitaxel and atezolizumab for the treatment of PD-L1-positive, metastatic triple-negative breast cancer: review and future directions. Kagihara JA; Andress M; Diamond JR Expert Rev Precis Med Drug Dev; 2020; 5(2):59-65. PubMed ID: 32190733 [TBL] [Abstract][Full Text] [Related]
5. Current State of Knowledge on the Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer Treatment: Approaches, Efficacy, and Challenges. Uchimiak K; Badowska-Kozakiewicz AM; Sobiborowicz-Sadowska A; Deptała A Clin Med Insights Oncol; 2022; 16():11795549221099869. PubMed ID: 35721387 [TBL] [Abstract][Full Text] [Related]
6. Acquired Treatment Resistance in a Patient with Metastatic PD-L1-Positive Breast Cancer and Germline BRCA1 Mutation. Kumeta T; Yamaguchi K; Hayami R; Arai K; Tsuneizumi M; Matsunuma R Case Rep Oncol; 2023; 16(1):544-551. PubMed ID: 37485016 [TBL] [Abstract][Full Text] [Related]
7. Atezolizumab in the treatment of metastatic triple-negative breast cancer. Pérez-García J; Soberino J; Racca F; Gion M; Stradella A; Cortés J Expert Opin Biol Ther; 2020 Sep; 20(9):981-989. PubMed ID: 32450725 [TBL] [Abstract][Full Text] [Related]
8. Immunotherapy in Triple-Negative Breast Cancer. Emens LA Cancer J; 2021 Jan-Feb 01; 27(1):59-66. PubMed ID: 33475294 [TBL] [Abstract][Full Text] [Related]
9. Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review. Li CH; Karantza V; Aktan G; Lala M Breast Cancer Res; 2019 Dec; 21(1):143. PubMed ID: 31842957 [TBL] [Abstract][Full Text] [Related]
10. Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer. Luo C; Wang P; He S; Zhu J; Shi Y; Wang J Front Oncol; 2022; 12():919072. PubMed ID: 35795050 [TBL] [Abstract][Full Text] [Related]
11. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. Schmid P; Adams S; Rugo HS; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Hegg R; Im SA; Shaw Wright G; Henschel V; Molinero L; Chui SY; Funke R; Husain A; Winer EP; Loi S; Emens LA; N Engl J Med; 2018 Nov; 379(22):2108-2121. PubMed ID: 30345906 [TBL] [Abstract][Full Text] [Related]
12. Positive progress: current and evolving role of immune checkpoint inhibitors in metastatic triple-negative breast cancer. Simmons CE; Brezden-Masley C; McCarthy J; McLeod D; Joy AA Ther Adv Med Oncol; 2020; 12():1758835920909091. PubMed ID: 33014143 [TBL] [Abstract][Full Text] [Related]
13. Atezolizumab (in Combination with Nab-Paclitaxel): A Review in Advanced Triple-Negative Breast Cancer. Kang C; Syed YY Drugs; 2020 Apr; 80(6):601-607. PubMed ID: 32248356 [TBL] [Abstract][Full Text] [Related]
14. Research advances and new challenges in overcoming triple-negative breast cancer. Zong Y; Pegram M Cancer Drug Resist; 2021; 4(3):517-542. PubMed ID: 34888495 [TBL] [Abstract][Full Text] [Related]
15. Role of Immunotherapy in the Treatment of Triple-Negative Breast Cancer: A Literature Review. K Patel K; Hassan D; Nair S; Tejovath S; Kahlon SS; Peddemul A; Sikandar R; Mostafa JA Cureus; 2022 Nov; 14(11):e31729. PubMed ID: 36569674 [TBL] [Abstract][Full Text] [Related]
16. Atezolizumab for the treatment of triple-negative breast cancer. Heimes AS; Schmidt M Expert Opin Investig Drugs; 2019 Jan; 28(1):1-5. PubMed ID: 30474425 [TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Mittendorf EA; Zhang H; Barrios CH; Saji S; Jung KH; Hegg R; Koehler A; Sohn J; Iwata H; Telli ML; Ferrario C; Punie K; Penault-Llorca F; Patel S; Duc AN; Liste-Hermoso M; Maiya V; Molinero L; Chui SY; Harbeck N Lancet; 2020 Oct; 396(10257):1090-1100. PubMed ID: 32966830 [TBL] [Abstract][Full Text] [Related]
18. Targeting immune pathways in breast cancer: review of the prognostic utility of TILs in early stage triple negative breast cancer (TNBC). Blackley EF; Loi S Breast; 2019 Nov; 48 Suppl 1():S44-S48. PubMed ID: 31839159 [TBL] [Abstract][Full Text] [Related]
19. Moving Towards Targeted Therapies for Triple-Negative Breast Cancer. Kagihara JA; Shagisultanova E; Afghahi A; Diamond JR Curr Breast Cancer Rep; 2021 Sep; 13(3):216-226. PubMed ID: 34457184 [TBL] [Abstract][Full Text] [Related]
20. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Schmid P; Rugo HS; Adams S; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Henschel V; Molinero L; Chui SY; Maiya V; Husain A; Winer EP; Loi S; Emens LA; Lancet Oncol; 2020 Jan; 21(1):44-59. PubMed ID: 31786121 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]